scispace - formally typeset
W

William A. Weiss

Researcher at University of California, San Francisco

Publications -  260
Citations -  27379

William A. Weiss is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medulloblastoma & Neuroblastoma. The author has an hindex of 70, co-authored 235 publications receiving 23216 citations. Previous affiliations of William A. Weiss include Dartmouth College & University of Chicago.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

TL;DR: It is found that p110alpha is the primary insulin-responsive PI3-K in cultured cells, whereas p110beta is dispensable but sets a phenotypic threshold for p110 alpha activity, which illustrates systematic target validation using a matrix of inhibitors that span a protein family.
Journal ArticleDOI

miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

TL;DR: Investigation of the role of microRNAs in regulating the differentiation and proliferation of neural stem cells and glioblastoma-multiforme tumor cells suggests that targeted delivery of microRNA-124 and/or micro RNA-137 to gliobeasts tumor cells may be therapeutically efficacious for the treatment of this disease.
Journal ArticleDOI

Principles and current strategies for targeting autophagy for cancer treatment.

TL;DR: The current understanding of the core components of the autophagy machinery and the functional relevance of autophile within the tumor microenvironment is described and how this knowledge has informed preclinical investigations combining the autophile inhibitor hydroxychloroquine (HCQ) with chemotherapy, targeted therapy, and immunotherapy is outlined.